Physician profile
Joy Meng
NPI 1174786123
$15,235.24
in general payments reported to CMS, 2019-2025
38 companies · $2,723 in 2025
The $2,723 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $913 · 2021: $2,203 · 2022: $2,389 · 2023: $3,046 · 2024: $3,580 · 2025: $2,723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,162 · Education: $172 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,162.27 |
| Education | $171.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,439.96 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $2,119.44 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $1,985.69 | 2021-2025 | Ingrezza, Ongentys |
| Arbor Pharmaceuticals, INC. | $1,230.41 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $720.08 | 2022-2025 | Rytary, Crexont |
| Avanir Pharmaceuticals, INC. | $700.81 | 2019-2022 | |
| Mdd US Operations, LLC | $686.87 | 2023-2025 | Gocovri, Apokyn |
| Sk Life Science, INC. | $571.21 | 2022-2025 | |
| Pfizer INC. | $514.52 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $383.84 | 2023-2025 | Nuedexta, Rexulti |
| Lundbeck LLC | $345.55 | 2022-2025 | Rexulti, Vyepti |
| Allergan, INC. | $324.38 | 2019-2022 | |
| Biogen, INC. | $279.64 | 2021-2022 | |
| Kyowa Kirin, INC. | $278.26 | 2022-2024 | Nourianz |
| Lilly USA, LLC | $270.48 | 2023-2025 | Kisunla, Amyvid, Zepbound |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $268.34 | 2021-2024 | Inbrija, Ampyra |
| Eisai INC. | $257.85 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $242.38 | 2022 | |
| Ge Healthcare | $229.93 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $221.36 | 2024-2025 | Inbrija, Xeomin |
| Acadia Pharmaceuticals INC | $187.77 | 2022-2025 | Nuplazid |
| Scilex Pharmaceuticals INC. | $144.63 | 2022-2024 | Ztlido |
| Adamas Pharmaceuticals, INC. | $142.23 | 2020-2021 | |
| Ucb, INC. | $99.43 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $72.00 | 2019 | |
| Argenx US, INC. | $65.19 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Biohaven Pharmaceuticals, INC. | $61.11 | 2021 | |
| Avion Pharmaceuticals | $59.36 | 2021-2022 | |
| Almatica Pharma LLC | $53.43 | 2022-2023 | Gralise |
| Merck Sharp & Dohme LLC | $51.95 | 2021-2022 | |
| Cala Health, INC. | $48.66 | 2025 | Cala Kiq |
| Amgen INC. | $40.77 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $29.70 | 2025 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $28.47 | 2024 | Acthar |
| Grifols USA, LLC | $22.18 | 2023 | Gamunex-C |
| Azurity Pharmaceuticals, INC. | $21.89 | 2025 | Horizant |
| Idorsia Pharmaceuticals US INC | $20.73 | 2024 | Quviviq |
| Horizon Therapeutics Plc | $14.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Meng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.